Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

INC Research Becomes First Global CRO to Offer Clinical Research Monitor Credential

Published: Thursday, September 12, 2013
Last Updated: Thursday, September 12, 2013
Bookmark and Share
Externally validated program sets global standard for measuring competence of clinical monitors.

INC Research has announced that it is the first global CRO to implement the Clinical Research Monitor Accreditation program, an internationally recognized standard for competence in clinical research monitoring offered through the International Academy of Clinical Research (IAoCR).

The new Clinical Credentialing program standardizes training of clinical research associates (CRAs) and establishes INC Research as the first accredited training center in the U.S.

"INC Research is committed to providing the best clinical development services to our biopharmaceutical partners, including the most highly trained and competent monitoring staff in the industry," said Alistair Macdonald, Chief Operating Officer.

Macdonald continued, "The Clinical Credential program will validate INC Research monitors' capabilities against globally recognized best practices, including recognition and reporting of adverse events, understanding regulatory processes, preparing for successful site initiations and site visits and more. Customers can therefore be confident the CRAs assigned to their studies are not only well trained and field tested, but also that their skills have been certified against an independent quality standard."

By ensuring its CRAs meet the Clinical Credentialing standard, INC is positioned to reduce risks to patients and lower error rates thereby helping to accelerate new treatments to market.

Exceptional training and global recognition of skills also is expected to help attract and retain top clinical research professionals.

Launched in direct response to the industry's growing demand for accreditation of clinical research professionals, IAoCR's credentialing process focuses on independent verification of an individual's ability to monitor clinical trials effectively in real-life situations.

INC Research will train its CRAs, beginning with entry-level monitors, according to the new IAoCR program, a process spanning two to three months including field tests.

"Competent monitors play an essential role in getting new treatments to market faster while protecting the rights and wellbeing of patients involved in clinical trials," said Jacqueline Johnson North, CEO of IAoCR. "That's why offering programs that regulate and standardize training for CRAs is so important. I commend INC Research for being the first global CRO to embrace this program."

Founded in 2011, IAoCR is fast becoming the globally recognized standard for accreditation of professionals working in the international clinical research industry. IAoCR courses and accreditations are recognized by educational institutes and employers globally and are mapped to international qualification frameworks.

Accreditations cover the depth and breadth of clinical research competencies and provide a far more accurate prediction of performance than simply years of experience.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

INC Research and Debiopharm Group ™ Announce Strategic Partnership
Debiopharm will entrust INC Research with the management of a clinical study linked to an important project in Debiopharm’s pipeline.
Wednesday, July 27, 2011
INC Research Completes Acquisition of Kendle International
Strategic combination creates leading global CRO well-positioned to capitalize on trends in drug development outsourcing.
Friday, July 15, 2011
INC Research to Acquire Kendle International for $15.25 per Share in Cash
INC Research will acquire Kendle in an all-cash transaction with a total equity value of approximately $232 million.
Tuesday, May 24, 2011
Patrick Melvin Joins Oncology Leadership Team at INC Research
Therapeutic and operational clinical trials expert strengthens oncology capabilities.
Thursday, February 17, 2011
INC Research Augments Pediatric Clinical Trial Capabilities
Kathy Bohannon brings valuable multi-discipline therapeutic expertise to pediatric trial design and management.
Friday, February 04, 2011
INC Research Expands Alliance Partnership Executive Team With New VP in Europe
INC Research, Inc. have announced Dr Manfred Weiler as VP of Alliance Development based in Europe. Based in Geneva, Dr. Weiler will lead INC Research's European effort to develop new clinical delivery alliances that are aimed at improving outsourced drug development.
Thursday, November 25, 2010
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos